Results 1 to 2 of 2

Thread: UCSD Findings Could Lead to New Therapy for Spinal Cord Injury-Induced Spasticity and

  1. #1
    Senior Member Jeremy's Avatar
    Join Date
    Jul 2001
    Location
    Canada
    Posts
    588

    UCSD Findings Could Lead to New Therapy for Spinal Cord Injury-Induced Spasticity and

    Date: October 16, 2007

    UCSD Findings Could Lead to New Therapy for Spinal Cord Injury-Induced Spasticity and Rigidity

    Research led by scientists at the University of California, San Diego (UCSD) School of Medicine has identified a target with potential as an effective new therapy for chronic spasticity and rigidity, a painful condition that often results from spinal cord injury.

    In work with rats, Martin Marsala, M.D., a professor in the Department of Anesthesiology at the University of California, San Diego (UCSD) School of Medicine, demonstrated that an AMPA receptor antagonist called NGX424 (tezampanel), being developed by TorreyPines Therapeutics, Inc., of La Jolla, California, is highly potent in suppressing spasticity and rigidity. The study will be published in the October 17 issue of the Journal of Neuroscience.

    Paraplegia from spinal cord ischemia is a serious complication that occurs in 20 to 40 percent of patients undergoing a surgical process called aortic cross-clamping. When the surgeon works on the aorta to correct a potentially lethal aneurysm, this large vessel carrying all of the blood flow from the heart must be temporarily blocked. If clamping occurs for more than 30 minutes, the procedure can result in the loss of specialized spinal cord neurons called spinal inhibitory neurons. Loss of these neurons can lead to irreversible spasticity and rigidity, or loss of muscle control, in the lower limbs.

    “This exaggerated muscle tone, or uncontrolled spasms, is a serious complication of either ischemic or traumatic injury to the spinal cord -- such as injuries resulting from a diving or car accident,” said Marsala. Several other conditions can lead to spasticity/rigidity, including brain trauma, multiple sclerosis, cerebral palsy or Parkinson’s disease – all of which lead to increased peripheral muscle tone.

    The most effective treatment for the spastic muscle condition – which results in pain and tremendous spasms, even in those patients who have partial motor recovery – has been a drug called Baclofen, a GABA-B receptor agonist that is delivered either systemically or spinally to patients. However, according to Marsala, patients taking this drug often develop tolerance and need increased dosage to achieve the same effect.

    “A new therapy to control spasticity is very important,” said lead author Michael P. Hefferan, Ph.D., of UCSD’s Department of Anesthesiology. “This AMPA receptor blockade offers a novel means of reducing the spasticity and rigidity in muscles because it works through a totally different receptor system than current drugs being used.”

    Spinal spasticity is the result of increased spinal neuronal excitability. The NGX424 compound – which is delivered via intrathecal catheters that inject the drug into the fluid surrounding the spinal cord – suppresses the AMPA-mediated neuronal excitation, relieving otherwise increased muscle tone.

    The authors also demonstrated that intrathecal delivery of GluR1 antisense (a treatment that blocks expression of one of the subunits in the AMPA receptor complex) provides a similar antispasticity effect. This further demonstrates a role for AMPA receptors in spasticity and rigidity, and indicates that blockade of this subunit by NGX424 likely plays a key role in the observed antispasticity effect.

    Marsala added that additional large animal safety testing will be required before the researchers can consider clinical trials in humans. However, the rat data from this study indicates no toxicity using infused NGX424. Subcutaneous delivery of the drug is currently being evaluated for treating migraines.

    Additional researchers include Karolina Kucharova, Kiyohiko Kinjo, Osamu Kakinohana, Tony L. Yaksh, UCSD Department of Anesthesiology; Gabriella Sekerkova, Feinberg School of Medicine, Northwestern University; Seiya Nakamura and Tatsuya Fuchigami, UCSD Department of Anesthesiology and University of the Ryukyus, Okinawa, Japan; Zoltan Tomori, Institute of Experimental Physics, Slovak Academy of Scineces; and Neil Kurtz, TorreyPines Therapeutics, Inc., La Jolla.

    Funding for the research was provided by the National Institutes of Health, an American Heart Association post-doctoral fellowship and TorreyPines Therapeutics Inc.

    ###

    Media Contact: Debra Kain, 619-543-6163, ddkain@ucsd.edu





    Related News

    The University of California, San Diego (UCSD) Med ...

  2. #2
    Senior Member Max's Avatar
    Join Date
    Jul 2001
    Location
    Montreal,Province of Quebec, CANADA
    Posts
    15,036

    Arrow Tezampanel, TorreyPines Therapeutics' Lead Compound, Reduced Muscle Spasticity and Ri

    Tezampanel, TorreyPines Therapeutics' Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
    Data Suggest Potential for Treating Motor System Disorders
    October 17, 2007: 08:30 AM EST

    LA JOLLA, Calif., Oct. 17 /PRNewswire/-- Tezampanel, a novel small molecule currently in clinical development by TorreyPines Therapeutics, Inc. for the treatment of acute migraine headache, was shown in an independent study to be effective in reversing or preventing muscle spasticity and rigidity in a rat model of spinal ischemia. These symptoms are commonly seen in Parkinson's disease, multiple sclerosis, cerebral palsy and other progressive motor system disorders caused by brain trauma or spinal cord injury.
    In a study published in the October 17 issue of the Journal of Neuroscience, a team of international researchers found that tezampanel, identified in the study as NGX424, reduced muscle spasticity (stimulus-dependent increase in muscle tone) and rigidity (continuous stimulus-independent increase in muscle tone) in the hind legs of spinal ischemia-induced paraplegic rats. In humans with motor system disorders, muscle spasticity and rigidity, often combined with painful perception, can interfere with rehabilitation and daily activities.
    The study was led by Michael P. Hefferan, Ph.D., and Martin Marsala, M.D., Anesthesiology Research Laboratory, Department of Anesthesiology, University of California, San Diego (UCSD). Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics, served as one of the study authors.

    http://money.cnn.com/news/newsfeeds/...17102007-1.htm

Similar Threads

  1. Question about methylpredisolone.
    By POPO367 in forum New SCI
    Replies: 3
    Last Post: 01-09-2007, 03:11 PM
  2. Replies: 10
    Last Post: 10-14-2004, 08:37 AM
  3. Neurotrauma - Posters by Keyword
    By Steven Edwards in forum Cure
    Replies: 2
    Last Post: 10-05-2004, 06:53 AM
  4. A fervent wish for the coming year
    By Wise Young in forum Cure
    Replies: 103
    Last Post: 01-11-2003, 09:54 PM
  5. Seneca - Ischemic SCI
    By Bareback Jack in forum Tranverse Myelitis, Multiple Sclerosis, Non-traumatic SCI
    Replies: 5
    Last Post: 12-13-2002, 06:58 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •